

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. A-64260-2/DJB/RMS

Anticipated Classification of E

this Application:

Class: 435

JAN 03 2002

Subclass:

Prior Application:

Examiner: VANDERVEGT, F.

Art Unit: 1816

Assistant Commissioner for Patents

BOX PATENT APPLICATION

Washington, DC 20231 Sir:

This is a request for filing a

Continuation

Divisional

application under 37 C.F.R. 1.60 of pending application Serial No. 08/789,333 filed on 23 January 1997

in the name of

Garry P. Nolan, Menlo Park, CA

(Names & Addresses of ALL Applicants)

for Methods for Screening for Transdominant Intra-Cellular Effector Peptides and RNA Molecules _____
(Title of Invention)

1. Enclosed is a copy of the prior application, including the oath or declaration, as originally filed.
(See 8(a) and (b) for drawing requirements.)
2. (a) Enclosed is a Small Entity Declaration.
- (b) A Small Entity Declaration is of record in the prior application.
3. The filing fee is calculated below:

Claims as filed in the prior application, less any claims canceled by amendment below:

	(Col. 1) NO. FILED	(Col. 2) NO. EXTRA	SMALL ENTITY RATE	OTHER THAN SMALL ENTITY RATE	OTHER THAN SMALL ENTITY FEE
BASIC FEE				\$395	\$790
TOTAL CLAIMS	<u>7</u>	<u>- 20 =</u>	<u>0</u>	<u>x 11 =</u>	<u>\$ 0</u>
INDEP CLAIMS	<u>2</u>	<u>- 3 =</u>	<u>0</u>	<u>x 41 =</u>	<u>\$ 0</u>
[] MULTIPLE DEPENDENT CLAIM PRESENTED			<u>+135 =</u>	<u>\$ 0</u>	<u>+270 =</u>
			TOTAL	\$395	TOTAL

If the difference in Col 1 is less than zero, enter "0" in Col. 2

4. The Commissioner is hereby authorized to charge any additional fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 06-1300 (Order No. A-*/*). A duplicate copy of this sheet is enclosed.

File No. A-64260-2/DJB/RMS

RECEIVED

JAN 04 2001

5. NO Check for filing is enclosed.

6. Cancel in this application original claims 1-15 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

7. Amend the specification by inserting before the first line the sentence:
--This is a division of application Serial No. 08/789,333 filed 23 January 1997.

8. (a) Informal drawings are enclosed.

(b) Formal drawings are enclosed **[4 SHEETS]**.

9. (a) Priority of application Serial No. _____ filed on _____ in _____ is claimed under 35 U.S.C. 119.

(b) The certified copy has been filed in prior application Serial No. _____ filed on _____.

10. The prior application is assigned of record to Rigel Pharmaceuticals, Inc..

11. The power of attorney from the inventor in the prior application is to:

FLEHR HOHBACH TEST ALBRITTON & HERBERT, LLP
Suite 3400, Four Embarcadero Center
San Francisco, California 94111-4187
Telephone: (415) 781-1989

(a) The power from the inventor appears in the original papers in the prior application.

(b) Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

(c) A new power from assignee will be executed and forwarded.

(d) Address all future communications to:

FLEHR HOHBACH TEST ALBRITTON & HERBERT, LLP
Suite 3400, Four Embarcadero Center
San Francisco, California 94111-4187
Telephone: (415) 781-1989

12. A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

13. I hereby verify that the attached papers are a true copy of prior application Serial No. 08/789,333 as originally filed on 23 January 1997.

File No. A-64260-2/DJB/RMS

Date: November 3, 1997

Robin M. Silva

Robin M. Silva
Reg. No. 38,304

XX Attorney or agent of record
Filed under Section 1.34(a)

Address of Signer:

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP
Four Embarcadero Center, Suite 3400
San Francisco, CA 94111

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: _____

Signature

(Not required if signed above by attorney.)

Inventor(s)

Assignee of complete interest

Address of Signer:

File No. A-64260-2/DJB/RMS

UTILITY/DESIGN PATENT (Rule 1.60)

Rec'd in the U.S. Patent and Trademark Office on the date stamped hereon via
Express Mail #: **EM554258349US**

Atty. Docket # **A-64260-2/DJB/RMS**

Applicant: **NOLAN, Garry**

Cont. of Ser. No.: **08/789,333**

Filed: **23 January 1997**

Title: **Methods for Screening for Transdominant Intra-Cellular Effector Peptides and RNA Molecules**

Filed: **HEREWITH - November 3, 1997**

- ▶ Rule 1.60 Transmittal in 3 pages
- ▶ Copy of prior application in 84 pages, including claims and abstract
- ▶ 4 Sheets **FORMAL** drawings
- ▶ Copy of prior declaration in 2 pages
- ▶ NO Check for filing fee is enclosed

68698 U.S. PTO
08/963368



11/03/97

Express Mail Certificate: **EM554258349US - November 3, 1997**

RMS

FILING RECEIPT



UNITED STATES ~~ART~~ MENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY AND COMMISSIONER
OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/963,368	11/13/97	1801	\$0.00	A-64260-2/DJ	4	7	2

11/3/97

~~H~~
FLEX~~R~~ HOHBACH TEST ALBRITTON & HERBERT
SUITE 3400
FOUR EMBARCADERO CENTER
SAN FRANCISCO CA 94111-4187

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s) **GARRY**
GERRY P. NOLAN, MENLO PARK, CA.

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A DIV OF 08/789,333 01/23/97 now U.S. Patent No. 6,153,32
 WHICH IS A DIV OF 08/589,108 01/23/96
 WHICH IS A DIV OF 08/589,911 01/23/96 ABN-
 AND A CON OF 08/787,738 01/23/97 ~~PENDING~~
 WHICH ARE BOTH CIPS OF 08/589,109 01/23/96 and 08/589,911 01/23/96

FOREIGN FILING LICENSE GRANTED 12/27/97

TITLE

METHODS FOR SCREENING FOR ~~TRANSDOMINAT~~ INTRACELLULAR EFFECTOR ~~PEPTIDES~~
AND RNA MOLECULES~~TRANSDOMINANT~~~~PEPTIDES~~

PRELIMINARY CLASS: 536

RECEIVED

JAN 04 2001

OFFICE OF PETITIONS
DEPUTY A/C PATENTS

11:33